Navigation Links
Founder of ILEX Oncology and Triton Biosciences, Richard Love, Joins Board of Directors of Cell Therapeutics, Inc. (CTI)
Date:9/23/2007

SEATTLE, Sept. 24 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq and MTAX: CTIC) today announced that Richard L. Love has joined its board of directors. Love was the Chairman of the Board for Systems Medicine, which was recently acquired by CTI. Systems Medicine, which works with the Translation Genomics Institute ("TGen") in Arizona, uses the latest drug development technology to discover weak spots in a disease's genetic make-up and identify which drugs will be most effective at treating the disease.

James A. Bianco, M.D., President and CEO of CTI said, "Dick brings a wealth of entrepreneurial and drug development experience in the biopharmaceutical industry to CTI's board. We look forward to his input as we move toward the commercialization of pixantrone, XYOTAX(TM), and Brostallicin."

Love has worked in the industry for more than 40 years, including 27 years of bioscience leadership experience. He founded two biopharmaceutical companies, Triton Biosciences Inc. and ILEX Oncology, Inc. Love was CEO at both companies, and leading the clinical development teams in the creation of four drugs currently in use -- Betaseron(R), a treatment for multiple sclerosis, two treatments for chronic lymphocytic leukemia, Fludara(R) and CAMPATH(R), and Clolar(R), a treatment for acute leukemias.

"We are very excited to have Dick join CTI's board, and look forward to utilizing his industry expertise," said Phillip M. Nudelman, Ph.D., Chairman of the Board of CTI. "His leadership experience makes him a great addition to the board."

In addition to CTI, Love is currently Chairman of the Board of ImaRx Therapeutics, and he serves on the boards of PAREXEL International, and Molecular Profiling Institute. He previously served on the board of Xilas Medical, Inc. Love has been active with various non-profit organizations as well, serving on the boards of the Cancer Therapy and Research Center (CTRC) in San Antonio, TX, and the Translation Genomics Research Institute (TGen) in Phoenix, AZ.

"I am thrilled to join the CTI board and to have the opportunity to help the company reach its goal of making cancer more treatable," said Love. "I am fully committed to the Company's mission and look forward to contributing my experience to the development of both the Company and its drug candidates."

Mr. Love holds Bachelors and Masters of Science degrees in Chemical Engineering from the Virginia Polytechnic Institute.

In addition to Love, CTI's Board of Directors includes Phillip M. Nudelman, Ph.D., Chairman of the Board, President and Chief Executive of The Hope Heart Institute and former President and CEO of Group Health Cooperative; Frederick W. Telling, Ph.D., former Corporate Officer and Vice President of Corporate Policy and Strategic Management for Pfizer Inc.; Vartan Gregorian, Ph.D., President of Carnegie Corporation of New York; Mary O. Mundinger, Dr. PH, Dean and Professor, School of Nursing and Associate Dean, Faculty of Medicine, Columbia University; John H. Bauer, former EVP of Finance for Nintendo of America, Inc.; James A. Bianco, M.D., President and CEO of CTI; and Jack W. Singer, M.D., Chief Medical Officer of CTI.

About Cell Therapeutics, Inc.

Headquartered in Seattle, CTI is a biopharmaceutical company committed to developing an integrated portfolio of oncology products aimed at making cancer more treatable. For additional information, please visit http://www.cticseattle.com.

Media Contact:

Dan Eramian

T: 206.272.4343

C: 206.854.1200

Susan Callahan

T: 206.272.4472

F: 206.272.4434

Lindsey Jesch

T: 206.272.4347

E: media@ctiseattle.com

http://www.cticseattle.com/media.htm

Investors Contact:

Leah Grant

T: 206.282.7100

F: 206.272.4434

E: invest@ctiseattle.com

http://www.cticseattle.com/investors.htm


'/>"/>
SOURCE Cell Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Leadership insights from co-founder of Yesmail
2. John Bergman, co-founder of Guild Software
3. At Berbee, president replaces founder as CEO
4. Online Kiosks founder Mike Strand uses contest to screen new business plan
5. Third Wave co-founder shoots for small target in latest project
6. Entrepreneurial Profile: Kelly Henrickson, founder of Prodesse, Inc.
7. Strandware Founder Establishes Consulting Firm
8. Epics Founder Judy Faulkner Speaks on Culture, Business Beliefs, and Recruiting: WTN Exclusive Coverage
9. Interview: Billpoint Founder Jason May on eBay, Open Source
10. WTN Interview: Alex Bratton: EmailRXs founder on viruses and spam
11. ESR1 Gene Expression in Oncology and Metabolic Diseases Using the ASCENTATM System Target Validation and Identification of Novel Disease Indications
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... 2016 /PRNewswire/ - FACIT has announced the creation ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" or "the ... a portfolio of first-in-class WDR5 inhibitors for the ... WDR5 represent an exciting class of therapies, possessing ... for cancer patients. Substantial advances have been achieved ...
(Date:6/23/2016)...  The Biodesign Challenge (BDC), a university competition that ... living systems and biotechnology, announced its winning teams at ... New York City . The teams, ... at MoMA,s Celeste Bartos Theater during the daylong summit. ... curator of architecture and design, and Suzanne Lee ...
(Date:6/23/2016)... June 23, 2016 Apellis Pharmaceuticals, Inc. ... clinical trials of its complement C3 inhibitor, APL-2. ... multiple ascending dose studies designed to assess the ... subcutaneous injection in healthy adult volunteers. ... as a single dose (ranging from 45 to ...
(Date:6/23/2016)... ... June 23, 2016 , ... ... and technical consulting, provides a free webinar on Performing Quality Investigations: ... 2016 at 12pm CT at no charge. , Incomplete investigations are still a ...
Breaking Biology Technology:
(Date:5/16/2016)... YORK , May 16, 2016   EyeLock ... solutions, today announced the opening of an IoT Center ... to strengthen and expand the development of embedded iris ... an unprecedented level of convenience and security with unmatched ... authenticate one,s identity aside from DNA. EyeLock,s platform uses ...
(Date:5/9/2016)... UAE, May 9, 2016 Elevay ... comes to expanding freedom for high net worth professionals ... in today,s globally connected world, there is still no ... could ever duplicate sealing your deal with a firm ... passports by taking advantage of citizenship via investment programs ...
(Date:4/28/2016)... and BANGALORE, India , April 28, 2016 ... a product subsidiary of Infosys (NYSE: INFY ), ... a global partnership that will provide end customers ... mobile banking and payment services.      (Logo: ... innovation area for financial services, but it also plays a ...
Breaking Biology News(10 mins):